VYNE Therapeutics Inc. Fair Value Disclosure
| December 31, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Cash and cash equivalents | $ | 23,133 | $ | 894 | $ | — | $ | 24,027 | |||||||||||||||
| Marketable securities | — | 4,981 | — | 4,981 | |||||||||||||||||||
| Total assets | $ | 23,133 | $ | 5,875 | $ | — | $ | 29,008 | |||||||||||||||
| December 31, 2024 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Cash and cash equivalents | $ | 19,926 | $ | — | $ | — | $ | 19,926 | |||||||||||||||
| Marketable securities | — | 41,590 | — | 41,590 | |||||||||||||||||||
| Total assets | $ | 19,926 | $ | 41,590 | $ | — | $ | 61,516 | |||||||||||||||
Want the next VYNE Therapeutics Inc. fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment VYNE Therapeutics Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 27, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
| 2023 | Mar 1, 2024 | |
| 2021 | Mar 17, 2022 | |
| 2020 | Mar 4, 2021 | |
| 2019 | Mar 3, 2020 | |
| 2018 | Feb 28, 2019 | |
| 2017 | Mar 28, 2018 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.